Novavax Inc NVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Novavax to Participate in September Investor Conferences
-
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax — Update
-
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
-
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
-
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
-
Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant
Trading Information
- Previous Close Price
- $9.40
- Day Range
- $8.95–10.10
- 52-Week Range
- $6.20–13.39
- Bid/Ask
- $9.90 / $10.05
- Shares Outstanding
- 164.95M
- Market Cap
- $1.65B
- Volume/Avg
- 18,978 / 6M
Key Statistics
- Price/Earnings (Normalized)
- 60.37
- Price/Sales
- 4.03
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 749
- Website
- https://www.novavax.com
Valuation
|
Metric
|
NVAX
|
|---|---|
Price/Earnings (Normalized) | 60.37 |
Price/Book Value | — |
Price/Sales | 4.03 |
Price/Cash Flow | — |
Price/Earnings
NVAX
Financial Strength
|
Metric
|
NVAX
|
|---|---|
Quick Ratio | 2.23 |
Current Ratio | 2.33 |
Interest Coverage | −10.20 |
Quick Ratio
NVAX
Profitability
|
Metric
|
NVAX
|
|---|---|
Return on Assets (Normalized) | −10.63% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −70.18% |
Return on Assets
NVAX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@%sBxg@ | LOCK|<j&@$ | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|s&^GxM | LOCK|^G<KQ | $84B | |||
| Moderna Inc
MRNA
| LOCK|HQ&B<@$ | LOCK|?rC | $83B | |||
| argenx SE ADR
ARGX
| LOCK|C?^s#N | LOCK|K$M | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|PBX^L$> | LOCK|?&< | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>?X<VJ | LOCK|MC?# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!%<@<?Z | LOCK|wZtc | $29B | |||
| Incyte Corp
INCY
| LOCK|BQy<<x& | LOCK|Z# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|q^@hN?$ | LOCK|!>Q | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|yc?LJd | LOCK|qb | $14B |
United States